|
SMT201700023T1
(it)
|
2010-08-02 |
2017-03-08 |
Regeneron Pharma |
Topi che producono proteine leganti vl
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
WO2015077491A1
(en)
|
2013-11-20 |
2015-05-28 |
Regeneron Pharmaceuticals, Inc. |
Aplnr modulators and uses thereof
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
AU2015231025A1
(en)
|
2014-03-21 |
2016-09-15 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
BR112017001385B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
KR102476226B1
(ko)
|
2014-08-05 |
2022-12-12 |
아폴로믹스 인코포레이티드 |
항-pd-l1 항체
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CN107001461A
(zh)
|
2014-09-16 |
2017-08-01 |
瑞泽恩制药公司 |
抗胰高血糖素抗体及其使用方法
|
|
KR102614189B1
(ko)
*
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
|
RU2726446C2
(ru)
|
2014-11-24 |
2020-07-14 |
Регенерон Фармасьютикалз, Инк. |
Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
AU2015357543B2
(en)
|
2014-12-05 |
2021-10-21 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
EP3288976B1
(en)
|
2015-04-29 |
2020-04-08 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR101712638B1
(ko)
*
|
2015-08-19 |
2017-03-07 |
한국과학기술연구원 |
Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
|
|
AU2016325630B2
(en)
|
2015-09-23 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-CD3 bispecific antibodies and uses thereof
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
BR112018011336A2
(pt)
|
2015-12-04 |
2018-12-04 |
Memorial Sloan-Kettering Cancer Center |
anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
|
|
LT3394103T
(lt)
|
2015-12-22 |
2023-09-11 |
Regeneron Pharmaceuticals, Inc. |
Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
BR112018071285A2
(pt)
*
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores, vetor, sistema, e, método
|
|
SG11201807885PA
(en)
*
|
2016-04-20 |
2018-10-30 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
TWI910495B
(zh)
|
2016-05-13 |
2026-01-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
EP3470424B1
(en)
*
|
2016-06-08 |
2025-04-23 |
Shanghai Jiao Tong University School of Medicine |
Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
|
|
CN116769024A
(zh)
|
2016-06-14 |
2023-09-19 |
瑞泽恩制药公司 |
抗c5抗体及其用途
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
CN106191072A
(zh)
*
|
2016-08-04 |
2016-12-07 |
沈沭彤 |
重组人源嵌合GcFc基因片段及融合蛋白
|
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
|
MY199468A
(en)
|
2016-09-23 |
2023-10-31 |
Regeneron Pharma |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
JP7066690B2
(ja)
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｍｕｃ１６（ムチン１６）抗体
|
|
LT3538554T
(lt)
|
2016-11-08 |
2025-10-10 |
|
Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
EP4649966A3
(en)
|
2016-12-01 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
EA201991673A1
(ru)
|
2017-02-10 |
2020-01-17 |
Регенерон Фармасьютикалз, Инк. |
Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CN106831995A
(zh)
*
|
2017-03-31 |
2017-06-13 |
北京百特美博生物科技有限公司 |
新型双特异性抗体及其用途
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
EA201992630A1
(ru)
|
2017-05-06 |
2020-04-29 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
EA202090149A1
(ru)
|
2017-06-28 |
2020-05-31 |
Ридженерон Фармасьютикалз, Инк. |
Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
|
|
SG11202000073XA
(en)
|
2017-07-24 |
2020-02-27 |
Regeneron Pharma |
Anti-cd8 antibodies and uses thereof
|
|
TWI865430B
(zh)
|
2017-07-24 |
2024-12-11 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CA3076632A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CA3274059A1
(en)
|
2017-12-13 |
2026-03-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibody combinations and uses thereof
|
|
SG11202005146VA
(en)
|
2017-12-18 |
2020-06-29 |
Regeneron Pharma |
Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
|
|
CN109971720B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US20190218285A1
(en)
*
|
2018-01-18 |
2019-07-18 |
Molecular Cloning Laboratories (MCLAB) LLC |
Long-Acting Therapeutic Fusion Proteins
|
|
US11780907B2
(en)
|
2018-01-26 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to influenza hemagglutinin
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3772927B1
(en)
|
2018-03-24 |
2025-01-15 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
PT3773713T
(pt)
|
2018-04-06 |
2025-07-29 |
Regeneron Pharma |
Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
|
|
KR102871690B1
(ko)
|
2018-04-30 |
2025-10-16 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
AU2019288299B2
(en)
|
2018-06-19 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-factor XII/XIIa antibodies and uses thereof
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
CA3109513A1
(en)
|
2018-08-23 |
2020-02-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
|
|
CA3110513A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
KR20210082207A
(ko)
|
2018-10-23 |
2021-07-02 |
리제너론 파아마슈티컬스, 인크. |
항-npr1 항체 및 이의 용도
|
|
CA3110377A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
PH12021551476A1
(en)
|
2018-12-21 |
2022-04-25 |
Regeneron Pharma |
Rifamycin analogs and antibody-drug conjugates thereof
|
|
WO2020160242A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
|
KR20210126641A
(ko)
|
2019-02-12 |
2021-10-20 |
리제너론 파아마슈티컬스, 인크. |
보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
|
|
EP3927431A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
EP3927746A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
CA3134335A1
(en)
|
2019-03-22 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
Egfr x cd28 multispecific antibodies
|
|
JP7813582B2
(ja)
*
|
2019-04-18 |
2026-02-13 |
ジェネンテック， インコーポレイテッド |
抗体力価試験
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
EP3983015A1
(en)
|
2019-06-11 |
2022-04-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
|
|
EP3986934A1
(en)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
|
CN118526580A
(zh)
|
2019-06-21 |
2024-08-23 |
瑞泽恩制药公司 |
结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
|
|
BR112022002067A2
(pt)
|
2019-08-08 |
2022-06-14 |
Regeneron Pharma |
Formatos de molécula de ligação ao antígeno
|
|
US12077603B2
(en)
|
2019-08-15 |
2024-09-03 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
AU2020349462A1
(en)
|
2019-09-16 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging
|
|
IL292353A
(en)
|
2019-10-28 |
2022-06-01 |
Regeneron Pharma |
Anti-haemagglutinin antibodies and methods of using them
|
|
MX2022005330A
(es)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharma |
Moleculas de union multiespecificas con scfv en el extremo nterminal.
|
|
CN114929343B
(zh)
|
2019-12-06 |
2025-03-18 |
瑞泽恩制药公司 |
用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
|
|
WO2021127487A2
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN115243763A
(zh)
|
2020-01-08 |
2022-10-25 |
里珍纳龙药品有限公司 |
治疗进行性骨化性纤维发育不良
|
|
KR20220140802A
(ko)
|
2020-02-11 |
2022-10-18 |
리제너론 파아마슈티컬스, 인크. |
항-acvr1 항체 및 이의 용도
|
|
CN111411079B
(zh)
*
|
2020-03-27 |
2025-12-12 |
北京时合生物科技有限公司 |
细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
|
|
WO2021198880A1
(en)
*
|
2020-03-31 |
2021-10-07 |
Medimmune, Llc |
Stabilized igg4 antibodies and uses thereof
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
AU2021268026A1
(en)
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
|
WO2021231447A1
(en)
*
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Novel il10 agonists and methods of use thereof
|
|
BR112022024662A2
(pt)
|
2020-06-03 |
2023-04-04 |
Regeneron Pharma |
Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
|
|
US11197910B1
(en)
*
|
2020-08-19 |
2021-12-14 |
Vitruviae LLC |
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
KR20230069969A
(ko)
|
2020-09-15 |
2023-05-19 |
리제너론 파마슈티칼스 인코포레이티드 |
통증에 대한 lepr 아고니스트의 사용
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
MX2023003214A
(es)
|
2020-09-18 |
2023-05-24 |
Regeneron Pharma |
Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
|
|
JP2023544164A
(ja)
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
CA3195967A1
(en)
|
2020-10-28 |
2022-05-05 |
Xu Wang |
Vectorized anti-tnf-? antibodies for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US12325752B2
(en)
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
AU2022214319A1
(en)
|
2021-01-28 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
CA3219609A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
WO2022240877A1
(en)
|
2021-05-11 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss6 antibodies and uses thereof
|
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
KR20240046251A
(ko)
|
2021-08-16 |
2024-04-08 |
리제너론 파아마슈티컬스, 인크. |
신규 il27 수용체 효능제 및 그의 사용 방법
|
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
KR20240099460A
(ko)
|
2021-11-11 |
2024-06-28 |
리제너론 파아마슈티컬스, 인크. |
Cd20-pd1 결합 분자 및 이의 사용 방법
|
|
EP4437003A1
(en)
|
2021-11-24 |
2024-10-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
|
JP2024542823A
(ja)
|
2021-12-06 |
2024-11-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
|
|
US20230312718A1
(en)
|
2022-01-07 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc |
Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
US20230303719A1
(en)
|
2022-03-03 |
2023-09-28 |
Yale University |
Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
|
|
IL315405A
(en)
|
2022-03-17 |
2024-11-01 |
Regeneron Pharma |
Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
EP4507790A1
(en)
|
2022-04-11 |
2025-02-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
US20260034246A1
(en)
|
2022-05-03 |
2026-02-05 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
|
KR20250024872A
(ko)
|
2022-05-11 |
2025-02-19 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 결합 분자 전구단백질 및 이의 용도
|
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
CA3258187A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
KR20250035053A
(ko)
|
2022-06-07 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
|
|
CA3263388A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1
|
|
KR20250058123A
(ko)
|
2022-07-29 |
2025-04-29 |
리제너론 파마슈티칼스 인코포레이티드 |
항-TfR:페이로드 융합 및 이의 사용 방법
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
IL318426A
(en)
|
2022-08-02 |
2025-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
CN120051483A
(zh)
|
2022-08-18 |
2025-05-27 |
再生元制药公司 |
干扰素前蛋白及其用途
|
|
AU2023356866A1
(en)
|
2022-10-03 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
|
|
IL319818A
(en)
|
2022-10-10 |
2025-05-01 |
Regeneron Pharma |
Methods for reducing alloantibody levels in patients requiring solid organ transplantation
|
|
JP2026502768A
(ja)
|
2022-10-25 |
2026-01-27 |
アブレクシス， エルエルシー |
抗ｃｄ３抗体
|
|
WO2024092133A1
(en)
|
2022-10-27 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
EP4612184A1
(en)
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
AU2023379451A1
(en)
|
2022-11-14 |
2025-05-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
|
WO2024107731A2
(en)
|
2022-11-14 |
2024-05-23 |
Ablexis, Llc |
Anti-pd-l1 antibodies
|
|
KR20250116795A
(ko)
|
2022-11-14 |
2025-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
CN120380024A
(zh)
|
2022-12-21 |
2025-07-25 |
建新公司 |
抗pd-1×4-1bb结合蛋白
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
IL322055A
(en)
|
2023-01-13 |
2025-09-01 |
Regeneron Pharma |
IL12 receptor agonists and methods of using them
|
|
KR20250148746A
(ko)
|
2023-01-13 |
2025-10-14 |
리제너론 파아마슈티컬스, 인크. |
Fgfr3 결합 분자 및 그의 사용 방법
|
|
EP4665764A1
(en)
|
2023-02-13 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of muscle related disorders with anti-human cacng1 antibodies
|
|
TW202500587A
(zh)
|
2023-02-16 |
2025-01-01 |
法商賽諾菲公司 |
Cd40結合蛋白
|
|
EP4665410A1
(en)
|
2023-02-17 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
CN120857940A
(zh)
|
2023-02-17 |
2025-10-28 |
瑞泽恩制药公司 |
对cd3/taa双特异性抗体有反应的诱导型nk细胞
|
|
CN121057744A
(zh)
|
2023-02-28 |
2025-12-02 |
再生元制药公司 |
多价抗刺突蛋白结合分子及其用途
|
|
JP2026507123A
(ja)
|
2023-02-28 |
2026-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔ細胞活性化剤およびその使用方法
|
|
EP4673462A2
(en)
|
2023-02-28 |
2026-01-07 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
EP4709756A1
(en)
|
2023-05-10 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
CN121752592A
(zh)
|
2023-05-12 |
2026-03-27 |
再生元制药公司 |
干扰素受体拮抗剂及其用途
|
|
EP4724477A1
(en)
|
2023-06-11 |
2026-04-15 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
IL325163A
(en)
|
2023-06-16 |
2026-02-01 |
Regeneron Pharma |
CD40 × CD40 dual-specific antigen-binding molecules and their application
|
|
WO2025014913A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Bispecific pd-l1xcd28 antibodies and methods of use thereof
|
|
CN121568720A
(zh)
|
2023-07-10 |
2026-02-24 |
瑞泽恩制药公司 |
抗人类cacng1抗体-药物缀合物及其用途
|
|
CN121666401A
(zh)
|
2023-07-10 |
2026-03-13 |
瑞泽恩制药公司 |
双特异性PD-L1x4-1BB抗体及其使用方法
|
|
IL325613A
(en)
|
2023-07-19 |
2026-02-01 |
Regeneron Pharma |
Antibodies against factor xii/xiia and their uses
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
IL326018A
(en)
|
2023-07-28 |
2026-03-01 |
Regeneron Pharma |
Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
|
|
IL325956A
(en)
|
2023-08-02 |
2026-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28
|
|
KR20260049559A
(ko)
|
2023-08-02 |
2026-04-14 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
US20250114469A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
|
|
US20250154487A1
(en)
|
2023-11-10 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
TW202542187A
(zh)
|
2023-12-12 |
2025-11-01 |
美商再生元醫藥公司 |
以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025184603A2
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025199278A2
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked multispecific antigen-binding molecules with cleavable linkers
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
TW202548025A
(zh)
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20250376667A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
US20260055171A1
(en)
|
2024-06-11 |
2026-02-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
US20260000758A1
(en)
|
2024-06-28 |
2026-01-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
US20260014252A1
(en)
|
2024-07-11 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026039779A1
(en)
|
2024-08-15 |
2026-02-19 |
Yale University |
Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
WO2026050255A2
(en)
|
2024-08-27 |
2026-03-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026059919A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
|
|
WO2026059923A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
|
|
WO2026059920A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
|
|
WO2026059917A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors
|
|
WO2026059921A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
|
WO2026075989A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Engineered igg molecules and methods of use thereof
|